MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Santarus, Inc. (SNTS) Announces Inclusion Of UCERIS Phase III Extended Use Data In Presentation At Digestive Disease Week Meeting 0 comments
    May 21, 2012 2:17 PM | about stocks: SNTS

    Santarus, a specialty biopharmaceutical company focused on acquiring, developing, and commercializing proprietary products, announced that the safety and efficacy results concerning the investigational drug UCERIS™ (budesonide) 6 mg tablets (previously referred to as budesonide MMX®) in a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study will be featured in four poster presentations at the Digestive Convention Center on May 19 - 22, 2012.

    The study involved 123 patients, and was performed to evaluate the long-term safety and tolerability of UCERIS 6 mg. Additionally, the study assessed the effectiveness of UCERIS 6 mg in the maintenance of remission of ulcerative colitis compared to placebo, but the study was not designed to show statistical significance.

    The poster presentation schedule is shown below:

    Sunday, 8:00 a.m. - 5:00 p.m., May 20, 2012, Randomized Controlled Trials in IBD, San Diego Convention Center, Halls C - G

    • Su2087 - Effect of Long-Term Budesonide MMX 6 mg Use on Bone Mineral Density in Patients with Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended Use Study
    • Su2088 - Safety Analysis of Budesonide MMX 6 mg for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended Use Study
    • Su2080 - Efficacy of Budesonide MMX 6 mg QD for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12-Month Safety and Extended Use Study

    Tuesday, 8:00 a.m. - 5:00 p.m. May 22, 2012, Clinical IBD, San Diego Convention Center, Halls C - G

    • Tu1252 - Effect of Budesonide MMX 6 mg on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended Use Study

    The investigational drug UCERIS is a locally acting corticosteroid in an innovative, patented, oral tablet formulation, which utilizes proprietary MMX® multi-matrix system technology and is designed to result in the measured release and distribution of budesonide throughout the entire length of the colon. Budesonide has topical anti-inflammatory activity and, due to an extended first pass effect, has less systemic absorption than other corticosteroids. Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A., is collaborating with Santarus on the development of UCERIS.

    For more information, please visit www.santarus.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: SNTS
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.